Research and Markets: Global Kidney Cancer Drugs Market 2012-2016: AVEO Pharmaceuticals Inc., Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Novartis AG, and Pfizer Inc. Dominate the Market

Research and Markets (http://www.researchandmarkets.com/research/96c7js/global_kidney) has announced the addition of the "Global Kidney Cancer Drugs Market 2012-2016" report to their offering.

TechNavio's analysts forecast the Global Kidney Cancer Drugs market to grow at a CAGR of 13.4 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing demand in developing economies. The Global Kidney Cancer Drugs market has also been witnessing an increase in R&D activities. However, over-dependence of the market on the US could pose a challenge to the growth of this market.

This report has been prepared based on an in-depth market analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Kidney Cancer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Commenting on the report, an analyst from TechNavio's Healthcare team said: ''The vendors in this market are investing heavily in R&D to develop kidney cancer drugs from biological sources because this approach can increase the efficacy of the drugs. Moreover, vendors are formulating effective injection solutions that can help retain the efficacy of the drug molecule for a longer period. For instance, Pfizer Inc. is increasingly focusing on enhancing the efficacy of its kidney cancer drug Sutent. Moreover, vendors are increasing their investment in the R&D of drugs that can be used for the treatment of more than one type of cancer.''

According to the report, the US government has increased expenditure on healthcare because of the prevalence of several diseases, which are largely due to the changing lifestyles of individuals, environmental health hazards, and genetic disorders. As a result, the use of therapeutic drugs for the treatment of cancer has increased. Healthcare spending in the US has increased significantly. Thus, the opportunity for revenue generation has increased, which acts as a driver of the Kidney Cancer Drugs market in the US. Moreover, this increase in healthcare expenditure is expected to increase the quality of treatments as well as the number of R and D projects. This is one of the major drivers contributing to the growth of the Global Kidney Cancer Drugs market.

Further, the report states that the delay in diagnosing cancer is one of the major challenges in the Global Kidney Cancer Drugs market.

The key vendors dominating this market space are AVEO Pharmaceuticals Inc., Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Novartis AG, and Pfizer Inc.

The other vendors mentioned in the report are AstraZeneca plc, Onyx Pharmaceuticals Inc., Merck Serono S.A., and WILEX AG

Key questions answered in this report:

- What will the market size be in 2016 and what will the growth rate be?

- What are the key market trends?

- What is driving this market?

- What are the challenges to market growth?

- Who are the key vendors in this market space?

- What are the market opportunities and threats faced by the key vendors?

- What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of analyst time when you purchase this report. Details provided within the report.

For more information visithttp://www.researchandmarkets.com/research/96c7js/global_kidney